Natriuretic Peptides and Remodeling in Heart Failure

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Since the discovery of the cardiac hormone ANP, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure (HF). This new knowledge has underscored the importance of cardiorenal mechanisms that contribute to optimal cardiovascular homeostasis. Work has also established direct myocardial actions broadening their therapeutic potential beyond renal mechanisms. Indeed, one such therapeutic target is cardiac remodeling and fibrosis based upon the unique cardiorenal protective properties. The objective of this article is to review new insights into the use of natriuretic peptides as novel therapeutic agents for cardiorenal protection in progressive HF, which serves to limit cardiac remodeling and fibrosis and thus the progression of HF.

Original languageEnglish (US)
Pages (from-to)129-139
Number of pages11
JournalHeart Failure Clinics
Volume1
Issue number1
DOIs
StatePublished - Apr 2005

Fingerprint

Natriuretic Peptides
Heart Failure
Fibrosis
Translational Medical Research
Atrial Natriuretic Factor
Homeostasis
Therapeutics
Hormones
Kidney

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Natriuretic Peptides and Remodeling in Heart Failure. / Burnett, John C Jr.

In: Heart Failure Clinics, Vol. 1, No. 1, 04.2005, p. 129-139.

Research output: Contribution to journalArticle

@article{1b3f576dd17b4b6fa776ae9af23e4c6d,
title = "Natriuretic Peptides and Remodeling in Heart Failure",
abstract = "Since the discovery of the cardiac hormone ANP, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure (HF). This new knowledge has underscored the importance of cardiorenal mechanisms that contribute to optimal cardiovascular homeostasis. Work has also established direct myocardial actions broadening their therapeutic potential beyond renal mechanisms. Indeed, one such therapeutic target is cardiac remodeling and fibrosis based upon the unique cardiorenal protective properties. The objective of this article is to review new insights into the use of natriuretic peptides as novel therapeutic agents for cardiorenal protection in progressive HF, which serves to limit cardiac remodeling and fibrosis and thus the progression of HF.",
author = "Burnett, {John C Jr.}",
year = "2005",
month = "4",
doi = "10.1016/j.hfc.2005.01.002",
language = "English (US)",
volume = "1",
pages = "129--139",
journal = "Heart Failure Clinics",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Natriuretic Peptides and Remodeling in Heart Failure

AU - Burnett, John C Jr.

PY - 2005/4

Y1 - 2005/4

N2 - Since the discovery of the cardiac hormone ANP, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure (HF). This new knowledge has underscored the importance of cardiorenal mechanisms that contribute to optimal cardiovascular homeostasis. Work has also established direct myocardial actions broadening their therapeutic potential beyond renal mechanisms. Indeed, one such therapeutic target is cardiac remodeling and fibrosis based upon the unique cardiorenal protective properties. The objective of this article is to review new insights into the use of natriuretic peptides as novel therapeutic agents for cardiorenal protection in progressive HF, which serves to limit cardiac remodeling and fibrosis and thus the progression of HF.

AB - Since the discovery of the cardiac hormone ANP, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure (HF). This new knowledge has underscored the importance of cardiorenal mechanisms that contribute to optimal cardiovascular homeostasis. Work has also established direct myocardial actions broadening their therapeutic potential beyond renal mechanisms. Indeed, one such therapeutic target is cardiac remodeling and fibrosis based upon the unique cardiorenal protective properties. The objective of this article is to review new insights into the use of natriuretic peptides as novel therapeutic agents for cardiorenal protection in progressive HF, which serves to limit cardiac remodeling and fibrosis and thus the progression of HF.

UR - http://www.scopus.com/inward/record.url?scp=33645957347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645957347&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2005.01.002

DO - 10.1016/j.hfc.2005.01.002

M3 - Article

C2 - 17386839

AN - SCOPUS:33645957347

VL - 1

SP - 129

EP - 139

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 1

ER -